Compounded GLP-1 Peptides: Legal and Safety Status

Last updated: June 2026

Informational only. Not medical or legal advice. Compounded GLP-1 peptides are a contested regulatory area where the law has changed sharply in the past 18 months. This article describes the regulatory state, not a recommendation to use compounded GLP-1s. Verify with a licensed clinician and a healthcare attorney before any decision.

The compounded GLP-1 peptide market grew explosively from 2022 through early 2025 — fueled by the FDA-declared semaglutide and tirzepatide shortages, which created a § 503A and § 503B compounding pathway for copycats. That pathway has now closed. This guide maps the current legal and safety status of compounded GLP-1 peptides as of June 2026.

Are compounded GLP-1 peptides legal in 2026?

Largely no. The FDA declared the semaglutide shortage resolved on February 21, 2025, ending the § 503A and § 503B shortage exception that allowed compounding of copycat semaglutide. Tirzepatide compounding was further restricted by the January 2025 ITC General Exclusion Order blocking bulk tirzepatide imports. As of June 2026, only branded semaglutide (Ozempic, Wegovy, Rybelsus) and branded tirzepatide (Mounjaro, Zepbound) are legitimately available through licensed prescribers and pharmacies. The brief window of 503B-compounded copycats — which by 2024 was reportedly serving millions of patients through telehealth platforms — is now closed.

One narrow exception exists: § 503A pharmacies may still compound a patient-specific formulation when a clinically meaningful difference vs the FDA-approved product can be documented (e.g., a different dose, route, or excipient for a patient with a documented allergy). This is a narrow path, not a workaround for cost concerns. Compounded patient-specific semaglutide must be prescribed by a licensed clinician for a specific patient under § 503A authority and must demonstrate a clinical reason for compounding over using the branded product. For how the 503A and 503B paths now compare against cheaper brand self-pay options, see our compounded vs brand GLP-1 503A/503B landscape guide.

What changed in February 2025 — the semaglutide shortage resolution?

On February 21, 2025, the FDA officially declared the semaglutide shortage resolved, removing the legal basis for § 503A and § 503B compounding. During shortage status (originally declared March 2022), compounding pharmacies were permitted under the FD&C Act § 503A(b)(2) shortage exception to compound semaglutide for individual patients, and § 503B outsourcing facilities to compound in bulk for clinical use. Telehealth platforms (Hims & Hers, Ro, Henry Meds, Mochi Health, and many smaller players) had built business models on compounded semaglutide at $200-$400/month — versus $1,000-$1,400 for branded Ozempic or Wegovy retail.

The February 2025 resolution gave 503A pharmacies a 60-day wind-down and 503B outsourcing facilities a 90-day wind-down. By late May 2025, compounded semaglutide compounded under the shortage exception was no longer legal to dispense. Several major telehealth platforms pivoted to branded GLP-1s; others quietly continued under the patient-specific § 503A exception. Litigation continues — Hims & Hers and Outsourcing Facilities Association both have pending federal cases over the FDA's shortage-resolution declaration.

What about compounded tirzepatide?

Compounded tirzepatide had a parallel but harder regulatory ending. The FDA originally declared the tirzepatide shortage resolved in October 2024. After litigation, that resolution was vacated and reaffirmed in December 2024. The International Trade Commission then issued a General Exclusion Order (GEO) in January 2025 blocking imports of bulk tirzepatide active ingredient — effectively shutting down the supply chain for compounded copycats (USITC Investigation 337-TA-1370, 2025). As of June 2026, branded tirzepatide (Mounjaro, Zepbound) is the only legitimately available form.

Why did the FDA crack down on compounded GLP-1 vendors?

Three reasons: shortage resolution, quality concerns, and aggressive marketing practices. First, the shortage exception was always temporary — once Eli Lilly and Novo Nordisk could meet demand, the FDA was required to declare shortages resolved. Second, independent testing by multiple labs raised serious quality concerns about compounded GLP-1s. Third, several compounders were marketing copycat GLP-1s in ways that overlapped substantively with the branded products' marketing.

The FDA's enforcement timeline in 2024-2025:

• December 2024: Warning letters to 4 research peptide vendors (Prime Peptides, Xcel Peptides, SwissChems, Summit Research) for selling semaglutide, tirzepatide, and retatrutide as unapproved drugs (FDA warning letters, 2024)
• January 2025: ITC General Exclusion Order on tirzepatide imports
• February 21, 2025: FDA declares semaglutide shortage resolved
• June 2025: FDA raid on Amino Asylum; vendor goes offline
• March 6, 2026: Peptide Sciences (largest US gray-market vendor at ~$7.4M/month) voluntarily shuts down

For the broader peptide-vendor regulatory map see our peptide legality guide 2026.

<a id="status-table"></a>

Compounded GLP-1 legal status — at a glance (June 2026)

Product	Legal channel	Branded source	Compounded under § 503A?	Compounded under § 503B?	Typical cost (legitimate)	Notes
Semaglutide	Rx	Ozempic, Wegovy, Rybelsus (Novo Nordisk)	Patient-specific exception only — narrow	No (shortage exception ended Feb 2025)	$1,000-$1,400/mo retail	FDA-approved for T2D, weight management, CV risk reduction
Tirzepatide	Rx	Mounjaro, Zepbound (Eli Lilly)	Patient-specific exception only — narrow	No (shortage exception vacated, GEO blocks imports)	$1,000-$1,200/mo retail	FDA-approved for T2D, weight management
Retatrutide	None	Not yet approved (Lilly Phase 3)	No	No	Not legitimately available	Triple agonist; Lilly Phase 3 (TRIUMPH) trials
Liraglutide	Rx	Victoza, Saxenda (Novo Nordisk)	No (not on shortage list)	No	$700-$1,400/mo retail	Older daily GLP-1
Dulaglutide	Rx	Trulicity (Eli Lilly)	No	No	$900-$1,000/mo retail	Weekly GLP-1
Compounded "semaglutide blend" via gray market	Not legal	Unapproved	No	No	$200-$400/mo (gray market)	Sold by online "research" vendors; not legal for human use

What are the safety concerns with compounded GLP-1s?

Three quality concern categories: identity/purity, sterility, and dose accuracy. During the 2022-2024 shortage exception, compounded semaglutide was produced at varying quality levels. Some 503B outsourcing facilities operating under FDA-registered quality systems produced rigorously tested compounded semaglutide. Others — particularly later-stage telehealth-platform-affiliated 503A pharmacies — had less consistent oversight. Independent testing across the 2023-2025 period flagged multiple concerns:

• Identity: Some "semaglutide" products contained semaglutide-related impurities or salt forms (semaglutide sodium vs base) that weren't on the FDA-approved master file
• Dose accuracy: A 2024 JAMA Network Open test of 50 peptide products from online research vendors found 68% did not contain the labeled amount (range 0% to 187% of label) (peptide testing analysis, 2024)
• Sterility: 12% of tested products contained bacterial endotoxins above acceptable limits — a real injection-infection risk
• Contaminants: 22% contained undisclosed additives or contaminants

Independent testing by Finnrick Labs in 2025 corroborated these findings, with 37 retatrutide samples (from gray-market vendors selling unapproved triple-agonist GLP-1s) receiving failing grades across identity, purity, and contamination tests.

What are the legal risks for buyers of gray-market compounded GLP-1s?

Buyers face customs seizure risk, particularly on tirzepatide imports under the ITC GEO. Vendors face civil and criminal liability under the FD&C Act. The "research use only" labeling defense is no longer viable — FDA explicitly rejected it in the December 2024 warning-letter campaign. Federal criminal charges against peptide-vendor principals have shifted from theoretical to active (AMC Defense Law, 2026). The traditional pattern of "we sell to you for research, you decide what to do" no longer protects either side from enforcement.

For individuals: possession for personal use is not typically prosecuted, but importing from overseas risks customs seizure (specifically on tirzepatide under the ITC General Exclusion Order). The legal protection of a valid prescription for a branded GLP-1 is meaningful — the FDA enforcement focus has been on supply-side vendors and prescribing platforms, not individual patients.

What does the SOUL trial say about semaglutide's cardiovascular benefits?

The SOUL Randomized Clinical Trial — a 156-week study of oral semaglutide in patients with Type 2 diabetes and established CVD and/or CKD — provides current evidence for semaglutide's cardiovascular benefits. A post hoc secondary analysis showed oral semaglutide reduced systolic blood pressure, diastolic blood pressure, pulse pressure, total cholesterol, and triglycerides over 156 weeks vs placebo (SOUL trial cardiovascular analysis, JAMA Cardiology 2025). The primary endpoint showed significant reduction in first and total major adverse cardiovascular events (MACE). These findings — for branded oral semaglutide — were instrumental in FDA's January 2024 expanded approval for cardiovascular risk reduction in obese adults with established CVD (FDA Press Release, 2024).

These cardiovascular benefits are based on branded semaglutide as studied in the SOUL, SUSTAIN, STEP, PIONEER, and SELECT pivotal trials. Compounded versions have no equivalent trial evidence. Manufacturing variability in compounded GLP-1s — different salt forms, different excipients, varying potency — means the cardiovascular benefit profile cannot be extrapolated from branded trial data. For deep mechanism analysis, see our semaglutide mechanism of action research review.

Where does retatrutide fit?

Retatrutide is Eli Lilly's triple agonist (GLP-1 + GIP + glucagon receptor) currently in Phase 3 trials (TRIUMPH program). Phase 2 results published in 2023 showed dose-dependent weight loss up to ~24% at 48 weeks (NEJM 2023) — the most dramatic weight-loss results in any GLP-1-class peptide to date. Retatrutide is NOT FDA-approved and is not legally available for human use as of June 2026. Online "research chemical" retatrutide is widely sold via gray-market vendors but failed independent purity testing in 37 samples reviewed by Finnrick Labs in 2025. For the sourcing risks and why the only legal route is a clinical trial, see our guide on retatrutide as a research compound. Vendors selling retatrutide as a human-use product face the same FD&C Act enforcement as vendors selling semaglutide. See our retatrutide vs tirzepatide vs semaglutide triple agonist comparison for the dose and trial-result detail.

How to verify a compounding pharmacy or telehealth GLP-1 provider's legitimacy

For § 503A compounding pharmacies dispensing patient-specific GLP-1 compounds:

• Verify state board licensing — the pharmacy must be licensed in your state
• Confirm patient-specific authority — § 503A compounding requires a valid Rx for an individual patient with a documented clinical need beyond the branded product
• Request batch-specific COA — third-party identity and purity testing per batch
• Verify PCAB accreditation — Pharmacy Compounding Accreditation Board certification is the gold standard
• Check FDA's 503B outsourcing facility tracker — verify status if the platform claims § 503B compounding

For telehealth platforms prescribing compounded GLP-1s:

• Ask about the legal basis for compounding — if they cite "the shortage" you should walk away (the shortage is resolved)
• Ask which compounding pharmacy fills the prescription — verify that pharmacy independently
• Ask about ingredient source — bulk drug substance must come from FDA-registered suppliers

See our peptide vendor quality standards guide for the full evaluation framework.

Frequently asked questions

Are compounded GLP-1 peptides legal in 2026? Largely no. The FDA's February 21, 2025 shortage resolution for semaglutide and the January 2025 ITC GEO on tirzepatide have closed the § 503A and § 503B shortage-exception compounding pathways. Only a narrow patient-specific § 503A pathway remains for documented clinical need beyond the branded product.

Can I get compounded semaglutide cheaper than branded Ozempic? Not through legitimate channels as of June 2026. The compounding-pharmacy pathway that drove $200-$400/month compounded semaglutide pricing has closed. Branded semaglutide runs $1,000-$1,400/month retail; manufacturer copay programs and patient-assistance programs are the legitimate cost-reduction paths.

What happens if I'm currently on compounded semaglutide? Talk to your prescriber now. Most telehealth platforms have transitioned patients to branded semaglutide or tirzepatide. If your platform is still dispensing compounded semaglutide under the shortage exception (illegal since May 2025), the product source carries legal and quality risk.

Are gray-market "research chemical" GLP-1s safe? The 2024 JAMA Network Open testing showed 68% of online research peptides had wrong labeled dose; 12% had endotoxin contamination; 22% had undisclosed contaminants. The injection-related infection risk and dose-uncertainty risks are real. Independent testing of retatrutide samples in 2025 was uniformly negative.

Will the FDA reverse course on the shortage declarations? Hims & Hers and the Outsourcing Facilities Association have pending federal litigation over the shortage-resolution declarations. The litigation outcomes will shape the path forward. As of June 2026, the declarations stand and compounded copycats under the shortage exception are not legal.

Related Reading

• Semaglutide mechanism of action: complete research review
• Retatrutide vs tirzepatide vs semaglutide: triple-agonist comparison
• Peptide legality guide 2026
• Where to buy peptides legally 2026
• Peptide vendor quality standards 2026

---

-- The Peptide Front Team